
Key Points
- 01Pfizer signs exclusive licensing deal with Starna Therapeutics for three pre-IND in vivo CAR-T autoimmune programs
- 02Starna to receive $330 million upfront and up to $2.3 billion in milestone payments, plus royalties
- 03Pfizer secures exclusive rights outside Greater China, with options to expand into that territory
- 04Agreement adds in vivo CAR-T technology rights in immunology and oncology and expands Pfizer’s I&I pipeline
Pfizer and Starna ink exclusive in vivo CAR-T pact
Pfizer has entered into an exclusive licensing agreement with Starna Therapeutics covering three pre-IND in vivo chimeric antigen receptor T-cell programs focused on treating autoimmune diseases. The arrangement grants Pfizer exclusive rights outside Greater China to develop, manufacture and commercialize these programs, with options to expand its territory to include Greater China. Starna will receive an upfront payment of $330 million and is eligible for up to $2.3 billion in development and commercial milestone payments, plus royalties on net sales of any approved products.
Under the agreement, Pfizer will lead clinical development of the in vivo CAR-T programs outside Greater China. The company plans to manufacture finished drug product for initial clinical trials using its U.S. facilities, consolidating early-stage development and production within its existing infrastructure.
Scope of rights and technology access
Beyond the three autoimmune programs, Pfizer obtains rights to use Starna’s proprietary in vivo CAR-T technology in inflammation and immunology, and in oncology. The licensing package also includes options for Pfizer to exclusively license compounds generated under a separate research collaboration between the two companies.
Pfizer will have sole and exclusive control over commercialization outside Greater China for all products developed under the agreement. The company also retains options to expand its territorial rights to include Greater China for each exclusively licensed compound and product, offering a path to broader geographic coverage over time.
Strategic fit with Pfizer’s pipeline
Pfizer states that the deal expands its Inflammation and Immunology pipeline by adding in vivo CAR-T programs aimed at autoimmune indications. The company intends to apply its RNA delivery expertise to cell therapy approaches enabled by Starna’s targeted lipid nanoparticle delivery platform and RNA technology.
In describing the rationale for the transaction, Pfizer’s Chief Inflammation and Immunology Officer characterized in vivo CAR-T as an emerging and promising approach for autoimmune diseases, highlighting its potential for patients whose current treatment options are inadequate. Starna’s chief executive said the company views its delivery and RNA technologies as a foundation for advancing in vivo CAR-T therapies in this setting.
Key Takeaways
- 01The agreement gives Pfizer broad control over three early-stage in vivo CAR-T autoimmune programs while concentrating commercial rights outside Greater China.
- 02Financial terms, including a $330 million upfront payment and up to $2.3 billion in milestones, underscore the strategic importance Pfizer places on in vivo CAR-T.
- 03Technology and option rights extend the deal beyond the initial programs, positioning Pfizer to build out cell therapy capabilities in inflammation, immunology and oncology.
References
- https://finance.yahoo.com/healthcare/articles/pfizer-enters-exclusive-licensing-agreement-114500881.html?.tsrc=rss
- https://rallies.ai/news/pfizer-signs-licensing-deal-with-starna-therapeutics-for-autoimmune-disease-treatments-c49da01c790b1a2f
- https://ng.investing.com/news/stock-market-news/pfizer-licenses-in-vivo-cart-programs-from-starna-for-330m-93CH-2815479
- https://www.tipranks.com/news/the-fly/pfizer-enters-exclusive-licensing-agreement-with-starna-therapeutics-thefly-news